Titre
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Biollaz, J.
Auteure/Auteur
Brunner, H. R.
Auteure/Auteur
Gavras, I.
Auteure/Auteur
Waeber, B.
Auteure/Auteur
Gavras, H.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0160-2446
Statut éditorial
Publié
Date de publication
1982-11
Volume
4
Numéro
6
Première page
966
Dernière page/numéro d’article
72
Langue
anglais
Notes
Journal Article
Résumé
Nineteen hypertensive patients were treated with increasing doses of the new angiotensin-converting enzyme inhibitor MK 421. Twenty milligrams orally reduced blood pressure from 180/112 +/- 6.8/3.6 (mean +/- SEM) to 160/100 +/- 6.5/3.3 mm Hg (p less than 0.005) while heart rate increased from 75 +/- 2 to 87 +/- 3 beats/min (p less than 0.005). Plasma converting enzyme activity was still markedly reduced 24 h following 2.5, 5, 10, or 20 mg MK 421 p.o. (p less than 0.001). In nine patients treated with 20 mg b.i.d. for up to 10 months, blood pressure was controlled, with the association of hydrochlorothiazide 50 mg q.d. in five. However, 12 to 16 h following the preceding drug administration, plasma angiotensin II and aldosterone were back to base-line levels. Analysis of plasma angiotensin II-renin relationships strongly suggests that converting enzyme blockade is not complete even 4 h after 20 mg MK 421 and starts to wear off already at 12 h. Thus, MK 421 20 mg taken orally twice daily, effectively reduces blood pressure, but does not constantly suppress plasma angiotensin II and aldosterone. Whether its long duration of action makes once daily administration possible has not yet been established.
Sujets
PID Serval
serval:BIB_4936E31D6031
PMID
Date de création
2009-03-04T14:04:49.144Z
Date de création dans IRIS
2025-05-20T16:28:59Z